Merriden will buy Halvard Bio for $2.1 billion after its kidney drug clears a key trial
The deal comes eight weeks after Halvard’s lead drug slowed kidney decline in a mid-stage trial. It is the year’s third biotech buyout over $2 billion.
The deal comes eight weeks after Halvard’s lead drug slowed kidney decline in a mid-stage trial. It is the year’s third biotech buyout over $2 billion.